The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Agenus Inc. ( Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced that France’s National Agency for ...

Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Jan. 16, 2026 /CNW/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a ...

Mirador Therapeutics, Inc. (Mirador), a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, today announced key ...

Brazil's Lula won't attend EU-Mercosur deal signing: presidency source Agenus Inc. ( Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center , positioning the company for ...

LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

New research reveals that bacteria inside tumors suppress the immune response, driving immunotherapy resistance in head and neck squamous cell carcinoma.

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...